• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Allergan alleges Imprimis makes, sells and promotes unapproved drugs – and Imprimis fires back

September 11, 2017 By Sarah Faulkner

GavelLast week, Allergan (NYSE:AGN) said that it filed lawsuits against Imprimis Pharmaceuticals (NSDQ:IMMY), Prescriber’s Choice and Sincerus Florida, claiming that the companies manufacture, sell and promote unapproved new drugs.

The pharmaceutical giant filed suit in the U.S. District Court for the Central District of California. Today, Imprimis fired back at Allergan, denying the allegations and saying that it plans to ‘aggressively defend itself against Allergan’s frivolous lawsuit.’

“Biopharmaceutical companies like Allergan have a duty to put the safety of their patients first. This commitment is the cornerstone of our manufacturing, marketing and advertising of our FDA-approved products,” Allergan said in prepared remarks. “Today, we have brought suit against companies that we believe stand in stark contrast to that commitment. Imprimis Pharmaceuticals, Inc., Prescriber’s Choice, Inc., and Sincerus Florida, LLC do not follow the established compounding regulations, engage in false and misleading advertising, and ultimately, put patients and physicians at risk by selling unapproved new drugs.”

“Allergan’s illegal, abusive, and anticompetitive actions aimed at maintaining its obscenely high drug prices reveal its true socially unconscious values,” Imprimis CEO Mark Baum countered in a press release. “Despite Allergan’s misuse of its massive resources against a lawful competitor, Imprimis is winning support where it counts the most: among the nation’s leading ophthalmologists, and the patients that together we serve.”

Imprimis characterized Allergan as a ‘well-known professional litigant’, pointing towards issues like ongoing investigations into the company’s marketing and drug pricing practices.

Imprimis also described Allergan’s latest move to sell patents for its Restasis drug to a Native American tribe as an attempt to ‘thwart the US legal system and avoid lower-cost generic competition’.

Last week, Allergan said it transferred the patent rights for its opthalmic formulation of cyclosporine to the St. Regis Mohawk Tribe. Patented intellectual property owned by the tribe is protected from inter partes review challenges thanks to the tribe’s sovereign immunity – and it just so happens that last December, the U.S. Patent Office granted an inter partes review of Allergan’s Restasis patents.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Imprimis Pharmaceuticals

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS